These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 17785486)

  • 1. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.
    Okin PM; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Dahlöf B;
    Ann Intern Med; 2007 Sep; 147(5):311-9. PubMed ID: 17785486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
    Okin PM; Wachtell K; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Julius S; Lindholm LH; Nieminen MS; Edelman JM; Hille DA; Dahlöf B
    JAMA; 2006 Sep; 296(10):1242-8. PubMed ID: 16968848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
    Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Wedel H; Lindholm LH; Dahlöf B;
    JAMA; 2004 Nov; 292(19):2343-9. PubMed ID: 15547161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
    Okin PM
    J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study.
    Larstorp AC; Okin PM; Devereux RB; Olsen MH; Ibsen H; Dahlöf B; Kjeldsen SE; Wachtell K
    Am J Hypertens; 2012 Oct; 25(10):1101-9. PubMed ID: 22717544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review.
    Bang CN; Devereux RB; Okin PM
    J Electrocardiol; 2014; 47(5):630-5. PubMed ID: 25052475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure.
    Okin PM; Wachtell K; Gerdts E; Dahlöf B; Devereux RB
    J Hypertens; 2014 Dec; 32(12):2472-8; discussion 2478. PubMed ID: 25340854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients.
    Okin PM; Hille DA; Kjeldsen SE; Lindholm LH; Edelman JM; Dahlöf B; Devereux RB
    Am J Hypertens; 2010 Jul; 23(7):786-93. PubMed ID: 20395941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study.
    Okin PM; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Lindholm LH; Dahlöf B;
    Hypertension; 2007 Nov; 50(5):984-90. PubMed ID: 17893425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
    Larstorp AC; Okin PM; Devereux RB; Olsen MH; Ibsen H; Dahlöf B; Kjeldsen SE; Wachtell K
    J Hum Hypertens; 2011 Mar; 25(3):178-85. PubMed ID: 20505749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
    Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Dahlof B;
    Circulation; 2003 Aug; 108(6):684-90. PubMed ID: 12885747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of heart failure hospitalizations with combined electrocardiography and echocardiography criteria for left ventricular hypertrophy.
    Gerdts E; Okin PM; Boman K; Wachtell K; Nieminen MS; Dahlöf B; Devereux RB
    Am J Hypertens; 2012 Jun; 25(6):678-83. PubMed ID: 22456225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
    Wachtell K; Okin PM; Olsen MH; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Nieminen MS; Thygesen K
    Circulation; 2007 Aug; 116(7):700-5. PubMed ID: 17664372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension.
    Okin PM; Hille DA; Kjeldsen SE; Devereux RB
    J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29151037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study.
    Oikarinen L; Nieminen MS; Toivonen L; Viitasalo M; Wachtell K; Papademetriou V; Jern S; Dahlöf B; Devereux RB; Okin PM;
    Am Heart J; 2003 May; 145(5):919-25. PubMed ID: 12766755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators.
    Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Dahlöf B
    Hypertension; 2000 Nov; 36(5):766-73. PubMed ID: 11082141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
    Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive patients with electrocardiographic left ventricular hypertrophy.
    Okin PM; Kamel H; Kjeldsen SE; Devereux RB
    J Hypertens; 2016 Sep; 34(9):1831-7. PubMed ID: 27254312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy.
    Okin PM; Kjeldsen SE; Julius S; Hille DA; Dahlöf B; Edelman JM; Devereux RB
    Eur Heart J; 2010 Sep; 31(18):2271-9. PubMed ID: 20601389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
    Okin PM; Devereux RB; Nieminen MS; Jern S; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Dahlöf B;
    Circulation; 2006 Jan; 113(1):67-73. PubMed ID: 16365195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.